Skip to main content
. 2017 Feb 17;8(11):18059–18069. doi: 10.18632/oncotarget.15437

Figure 5. In vivo study with [I-124]6 compound in colon carcinoma xenografted SCID mice.

Figure 5

(A) μPET/CT molecular imaging of COX-2 with [I-124]6 in HT29 (upper panel) and HCT-116 (lower panel) xenografted SCID mice at 4 h p.i. Arrows indicate tumor. (B) Uptake of [I-124]6 in HT29 and HCT-116 tumors (in kBq/g tissue) (upper panel, left); tumor to muscle uptake ratio of [I-124]6 in HT29 and HCT-116 tumor xenografted SCID mice (upper panel, reight) at 4 h p.i.; gamma counter analysis of [I-124]6 biodistribution in HT29-xenografted SCID mice at 4 h p.i. (in %ID/g tissue) (n = 5). (C) Immunhistological analysis of COX-1 and COX-2 in HT29 and HCT-116 xenografts. (D) Corresponding SDS and Western Blot analysis of COX-1 and COX-2 expression in HT29 and HCT-116 xenografts. Data are mean ± SD from five independent experiments. In B, *P < 0.05 by two-tailed Student´s t-test.